<DOC>
	<DOCNO>NCT02683083</DOCNO>
	<brief_summary>Primary purpose clinical study evaluate safety , biodistribution radiation dosimetry [ 131I ] -SGMIB Anti-HER2 VHH1 healthy volunteer patient HER2+ breast cancer . Secondary purpose clinical study evaluate tumor uptake [ 131I ] -SGMIB Anti-HER2 VHH1 patient HER2+ breast cancer .</brief_summary>
	<brief_title>Study Evaluate Safety , Biodistribution , Radiation Dosimetry Tumor Imaging Potential 131I-SGMIB Anti-HER2 VHH1 Healthy Volunteers Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Subjects include study meet follow criterion : Subjects give informed consent Subjects agree drink alcoholic beverage use drug study Subject blood parameter within normal range Age : least 18 year old Patients include study meet follow criterion : Patients give informed consent Patients agree drink alcoholic beverage use drug study Age : least 18 year old Patients local , locally advanced metastatic HER2+ breast carcinoma diagnose biopsied tissue immunohistochemistry fluorescence situ hybridization ( FISH ) . Patients include study one follow criterion applies : Pregnant patient Breast feeding patient Patients occupational exposure ionize irradiation Patients previous thyroid disorder Patients receive radiolabeled compound long halflife ( &gt; 7h ) diagnostic therapeutic purpose within last 2 day . Patients absolute contraindication thyroid blockage potassium iodide . Patients abnormal liver : ALT/AST &gt; 2 time normal value ; bilirubin &gt; 1.5 time normal value . Patients abnormal kidney function : &lt; 50 ml/min/1,73 m2 Patients recent ( &lt; 1 week ) gastrointestinal disorder ( CTCAE v4.0 grade 3 4 ) diarrhea major symptom Patients serious active infection Patients lifethreatening illness organ system dysfunction , opinion investigator would either compromise patient safety interfere evaluation safety test radiopharmaceutical Patients communicate reliably investigator Patients unlikely cooperate requirement study Patients increase risk death preexist concurrent illness Patients participate already study Patients participate previous trial AntiHER2 VHH1 Subjects include study one follow criterion applies : Pregnant subject Breast feeding subject Subjects occupational exposure ionize irradiation Subjects clinical significant disease concomitant therapy ( except contraception ) Subjects previous thyroid disorder Subjects receive radiolabeled compound long halflife ( &gt; 7h ) diagnostic therapeutic purpose within last 2 day . Subjects absolute contraindication thyroid blockage potassium iodide . Subjects abnormal liver : ALT/AST &gt; 2 time normal value ; bilirubin &gt; 1.5 time normal value . Subjects abnormal kidney function : &lt; 50 ml/min/1,73 m2 Subjects recent ( &lt; 1 week ) gastrointestinal disorder ( CTCAE v4.0 grade 3 4 ) diarrhea major symptom Subjects serious active infection Subjects lifethreatening illness organ system dysfunction , opinion investigator would either compromise subject safety interfere evaluation safety test radiopharmaceutical Subjects communicate reliably investigator Subjects unlikely cooperate requirement study Subjects increase risk death preexist concurrent illness Subjects participate already study Subjects participate previous trial AntiHER2 VHH1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>